{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:03:09Z","timestamp":1788908589294,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM23\/00033"],"award-info":[{"award-number":["CM23\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cmi.2025.12.027","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:51:44Z","timestamp":1767804704000},"page":"529-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales"],"prefix":"10.1016","volume":"32","author":[{"given":"Mercedes","family":"Delgado-Valverde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Perez-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"L\u00f3pez-Cerero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.12.027_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","article-title":"Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other gram-negative bacteria","volume":"10","author":"Hansen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.12.027_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","article-title":"Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections","volume":"76","author":"Ramos-Casta\u00f1eda","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/jac\/dkz125","article-title":"Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime\/avibactam","volume":"74","author":"Papadimitriou-Olivgeris","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","volume":"31","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.12.027_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2361007","article-title":"Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae","volume":"13","author":"Shi","year":"2024","journal-title":"Emerg Microbe Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00722-24","article-title":"Evolution of ceftazidime\u2013avibactam resistance driven by mutations in double-copy bla KPC-2 to bla KPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae","volume":"9","author":"Zhang","year":"2024","journal-title":"mSystems"},{"key":"10.1016\/j.cmi.2025.12.027_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107030","article-title":"Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based \u03b2-lactamase inhibitor combinations and cefiderocol","volume":"63","author":"Pilato","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.12.027_bib9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate","volume":"72","author":"Both","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib10","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000028","article-title":"Rapid communications Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019","volume":"25","author":"Galani","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2025.12.027_bib11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"Role of the outer membrane and porins in susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam","volume":"60","author":"Pag\u00e8s","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib12","doi-asserted-by":"crossref","first-page":"dlaf137","DOI":"10.1093\/jacamr\/dlaf137","article-title":"In vivo evolution of ceftazidime\u2013avibactam resistance in blaOXA-244-positive E. coli potentially linked to PBP3 insertion and mutations in acrB and PBP2","volume":"7","author":"Kocer","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.12.027_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02874-23","article-title":"Structural insights into the molecular mechanism of high-level ceftazidime\u2013avibactam resistance conferred by CMY-185","volume":"15","author":"Kawai","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.12.027_bib14","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107256","article-title":"Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability","volume":"64","author":"Tellapragada","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.12.027_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1047109","article-title":"Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli","volume":"13","author":"Ma","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2025.12.027_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00675-23","article-title":"blaKPC-2 overexpression and blaGES-5 carriage as major imipenem\/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China","volume":"67","author":"Li","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00918-22","article-title":"In vitro mechanisms of resistance development to imipenem-relebactam in KPC-producing Klebsiella pneumoniae","volume":"66","author":"Findlay","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s15010-025-02474-3","article-title":"Comparison of the in vitro activities and resistance mechanisms against imipenem\u2013relebactam and ceftazidime\u2013avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China","volume":"53","author":"Guo","year":"2025","journal-title":"Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00432-19","article-title":"Nacubactam enhances meropenem activity against carbapenem-resistant Klebsiella pneumoniae producing KPC","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107407","article-title":"In vitro antimicrobial activity of six novel \u03b2-lactam and \u03b2-lactamase inhibitor combinations and cefiderocol against NDM-producing Enterobacterales in China","volume":"65","author":"Liu","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.12.027_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01676-21","article-title":"Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales","volume":"66","author":"V\u00e1zquez-Ucha","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jac\/dkaf045","article-title":"Decreased susceptibility to cefepime\/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2","volume":"80","author":"Tellapragada","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jgar.2025.07.011","article-title":"Emerging resistance to novel \u03b2-lactam \u03b2-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants","volume":"44","author":"Hamza","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.12.027_bib25","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00021-21","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.12.027_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00191-22","article-title":"Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins disruption mediated resistance to imipenem\/relebactam and meropenem\/vaborbactam in a KPC-producing Klebsiella pneumoniae clinical isolate","volume":"66","author":"Gaibani","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib28","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/jac\/dky251","article-title":"In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China","volume":"73","author":"Zhou","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00208-24","article-title":"A molecular analysis of meropenem\u2013vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae","volume":"68","author":"Yasmin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02208-19","article-title":"Mutation of kvrA Causes OmpK35 and OmpK36 Porin downregulation and reduced meropenem-vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae","volume":"64","author":"Dulyayangkul","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgar.2025.03.006","article-title":"Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam","volume":"42","author":"Vaiana","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.12.027_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib35","doi-asserted-by":"crossref","first-page":"ofad500","DOI":"10.1093\/ofid\/ofad500.2131","article-title":"2513. CERTAIN-1 Subgroup analysis: a phase 3 study of cefepime-taniborbactam efficacy in the treatment of complicated urinary tract infections (cUTI)","volume":"10","author":"Dorr","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10096-023-04697-4","article-title":"Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain","volume":"43","author":"Hern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-\u03b2-lactamases produced in Escherichia coli and Pseudomonas aeruginosa","volume":"68","author":"Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","article-title":"NDM-9 resistance to taniborbactam","volume":"23","author":"Le Terrier","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic antibacterial activity of xeruborbactam in vitro: Assessing spectrum and mode of action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib40","article-title":"The emerging concern of IMP variants being resistant to the only IMP-type metallo-\u03b2-lactamase inhibitor, xeruborbactam","volume":"69","author":"Le Terrier","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib42","article-title":"ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate \u03b2-lactamase inhibitor ledaborbactam combined with ceftibuten","volume":"68","author":"Jacobs","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00934-22","article-title":"Ceftibuten-ledaborbactam activity against multidrug-resistant and extended-spectrum-\u03b2-lactamase-positive clinical isolates of Enterobacterales from a 2018-2020 global surveillance collection","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2024.04.014","article-title":"Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates","volume":"38","author":"Morrissey","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.12.027_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107150","article-title":"Activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double \u03b2-lactamases under high and low permeability conditions","volume":"63","author":"Blanco-Mart\u00edn","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.12.027_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/mdr.2015.0122","article-title":"Reduced susceptibility to cefepime in clinical isolates of Enterobacteriaceae producing OXA-1 beta-lactamase","volume":"22","author":"Torres","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2025.12.027_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib48","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04936-22","article-title":"In vitro activity of cefiderocol compared to other antimicrobials against a collection of metallo-beta-lactamase-producing gram-negative bacilli from southern Spain","volume":"11","author":"Delgado-Valverde","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.12.027_bib50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","article-title":"Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants","volume":"41","author":"Poirel","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib51","article-title":"The Effect of b-lactam antibiotics on the evolution of ceftazidime\/avibactam and cefiderocol resistance in KPC-producing Klebsiella pneumoniae","volume":"67","author":"Zhang","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib52","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/jac\/dkac221","article-title":"Evolution of \u03b2-lactamase-mediated cefiderocol resistance","volume":"77","author":"Fr\u00f6hlich","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib53","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA","volume":"74","author":"Klein","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.12.027_bib54","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","article-title":"In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol","volume":"77","author":"Kriz","year":"2024","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.cmi.2025.12.027_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01410-24","article-title":"Global molecular epidemiology of the incomplete CirA protein related to cefiderocol resistance in Klebsiella pneumoniae: a genome-based study","volume":"13","author":"Long","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.12.027_bib56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/antibiotics12040785","article-title":"In vitro activity of cefiderocol on multiresistant bacterial strains and genomic analysis of two cefiderocol resistant strains","volume":"12","author":"Padovani","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.cmi.2025.12.027_bib57","first-page":"703","article-title":"Mechanisms of cefiderocol resistance in carbapenemase-producing Enterobacterales: insights from comparative genomics","volume":"14","author":"Tristancho-Bar\u00f3","year":"2025","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"10.1016\/j.cmi.2025.12.027_bib58","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.12.027_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2025.12.027_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: a novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2025.12.027_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41426-018-0141-y","article-title":"Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae","volume":"7","author":"Zheng","year":"2018","journal-title":"Emerg Microbe Infect"},{"key":"10.1016\/j.cmi.2025.12.027_bib62","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/imo2.39","article-title":"Dual role of ramR mutation in enhancing immune activation and elevating eravacycline resistance in Klebsiella pneumoniae","volume":"1","author":"Yu","year":"2024","journal-title":"IMetaOmics"},{"key":"10.1016\/j.cmi.2025.12.027_bib63","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25006536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25006536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:18:19Z","timestamp":1777609099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25006536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1198743X25006536"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.12.027","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}